Hepatic artery infusion chemotherapy for liver metastases in small cell lung cancer.
[BACKGROUND] The prognosis for patients with small cell lung cancer (SCLC), who develop liver metastases (LM) is extremely poor, and treatment options are limited.
APA
Deng R, Lv J, et al. (2025). Hepatic artery infusion chemotherapy for liver metastases in small cell lung cancer.. Journal of cancer research and therapeutics, 21(6), 1147-1152. https://doi.org/10.4103/jcrt.jcrt_1171_25
MLA
Deng R, et al.. "Hepatic artery infusion chemotherapy for liver metastases in small cell lung cancer.." Journal of cancer research and therapeutics, vol. 21, no. 6, 2025, pp. 1147-1152.
PMID
41474237
Abstract
[BACKGROUND] The prognosis for patients with small cell lung cancer (SCLC), who develop liver metastases (LM) is extremely poor, and treatment options are limited. This study aimed to evaluate the efficacy and safety of hepatic arterial infusion (HAI) chemotherapy combined with systemic chemotherapy for patients diagnosed with LM-SCLC.
[SUBJECT AND METHODS] From January 2019 to December 2023, HAI catheter systems were implanted in 15 patients with LM-SCLC, guided by digital subtraction angiography. All patients received systemic chemotherapy in combination with HAI using gemcitabine and floxuridine (FUDR).
[RESULTS] The overall response rate for intrahepatic lesions was 66.7%, including one patient (6.7%) with a complete response and nine (60.0%) with a partial response. Additionally, the median overall survival (mOS) was 13 months (95% confidence interval, 11.4-14.6 months). Notably, none of the patients experienced grade 4 adverse effects. However, the grade 3 adverse effects included leukopenia and neutropenia, which were well tolerated by all the patients.
[CONCLUSIONS] HAI of gemcitabine and FUDR, alongside systemic chemotherapy, may serve as an effective treatment strategy for achieving a high local response and prolonging mOS in patients with LM-SCLC, while also being associated with a relatively low incidence of adverse effects.
[SUBJECT AND METHODS] From January 2019 to December 2023, HAI catheter systems were implanted in 15 patients with LM-SCLC, guided by digital subtraction angiography. All patients received systemic chemotherapy in combination with HAI using gemcitabine and floxuridine (FUDR).
[RESULTS] The overall response rate for intrahepatic lesions was 66.7%, including one patient (6.7%) with a complete response and nine (60.0%) with a partial response. Additionally, the median overall survival (mOS) was 13 months (95% confidence interval, 11.4-14.6 months). Notably, none of the patients experienced grade 4 adverse effects. However, the grade 3 adverse effects included leukopenia and neutropenia, which were well tolerated by all the patients.
[CONCLUSIONS] HAI of gemcitabine and FUDR, alongside systemic chemotherapy, may serve as an effective treatment strategy for achieving a high local response and prolonging mOS in patients with LM-SCLC, while also being associated with a relatively low incidence of adverse effects.
MeSH Terms
Humans; Liver Neoplasms; Male; Lung Neoplasms; Small Cell Lung Carcinoma; Female; Infusions, Intra-Arterial; Middle Aged; Gemcitabine; Aged; Deoxycytidine; Hepatic Artery; Antineoplastic Combined Chemotherapy Protocols; Floxuridine; Treatment Outcome; Prognosis; Retrospective Studies
같은 제1저자의 인용 많은 논문 (5)
- CPGPrompt: translating clinical guidelines into large language model-executable decision support.
- The NPC1/USP7/p53 axis regulates cholesterol and promotes the proliferation of hepatocellular carcinoma.
- Comprehensive Evaluation of Targeted and Perilesional Biopsy in Biopsy-Naïve Patients With Prostate Positive Magnetic Resonance Imaging: PERI-PRO Noninferiority Randomized Controlled Trial.
- Integrated multi-omics analysis and functional validation reveal the role of TRIM2 as a potential novel biomarker in breast cancer.
- Induction chemotherapy followed by radiotherapy in primary small cell neuroendocrine carcinoma of the parotid gland: a case report and literature review.